
Alpine Immune Sciences ALPN
Quarterly report 2024-Q1
added 05-09-2024
Alpine Immune Sciences Total Current Liabilities 2011-2026 | ALPN
Annual Total Current Liabilities Alpine Immune Sciences
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 58 M | 69.8 M | 41.2 M | 8.68 M | 8.13 M | 1.9 M | 6.5 M | 4.42 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 69.8 M | 1.9 M | 24.8 M |
Total Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
I-Mab
IMAB
|
576 M | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
1.62 B | - | - | $ 40.3 B | ||
|
Apellis Pharmaceuticals
APLS
|
324 M | $ 20.2 | -2.42 % | $ 2.55 B | ||
|
Aptorum Group Limited
APM
|
4.34 M | $ 0.82 | -2.95 % | $ 4.47 M | ||
|
Axsome Therapeutics
AXSM
|
379 M | $ 166.62 | 0.14 % | $ 8.29 B | ||
|
AbCellera Biologics
ABCL
|
64.3 M | $ 3.74 | -2.23 % | $ 1.12 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
1.77 M | - | -1.52 % | $ 24.7 M | ||
|
Codexis
CDXS
|
23.6 M | $ 0.98 | -3.72 % | $ 71.9 M | ||
|
Catalyst Pharmaceuticals
CPRX
|
147 M | $ 23.95 | 0.29 % | $ 2.93 B | ||
|
Adverum Biotechnologies
ADVM
|
22.9 M | - | - | $ 86.2 M | ||
|
Corvus Pharmaceuticals
CRVS
|
6.87 M | $ 17.56 | -1.84 % | $ 843 M | ||
|
Champions Oncology
CSBR
|
23.9 M | $ 5.98 | -1.48 % | $ 81.7 M | ||
|
Институт стволовых клеток человека
ISKJ
|
556 M | - | - | - | ||
|
ARCA biopharma
ABIO
|
13 M | - | 1052.0 % | $ 415 M | ||
|
Acer Therapeutics
ACER
|
19 M | - | 2.71 % | $ 14 M | ||
|
Eton Pharmaceuticals
ETON
|
16.2 M | $ 17.77 | -2.09 % | $ 456 M | ||
|
Exelixis
EXEL
|
406 M | $ 40.92 | -0.27 % | $ 11.1 B | ||
|
Acorda Therapeutics
ACOR
|
228 M | - | -24.86 % | $ 820 K | ||
|
Capricor Therapeutics
CAPR
|
31.3 M | $ 25.91 | -3.54 % | $ 694 M | ||
|
Galectin Therapeutics
GALT
|
35.4 M | $ 2.9 | -5.39 % | $ 181 M | ||
|
Acasti Pharma
ACST
|
1.93 M | - | 4.01 % | $ 150 M | ||
|
Greenwich LifeSciences
GLSI
|
1.56 M | $ 27.35 | -0.15 % | $ 356 M | ||
|
Galecto
GLTO
|
5.83 M | $ 29.97 | -0.27 % | $ 796 M | ||
|
Gossamer Bio
GOSS
|
51.6 M | $ 0.46 | 8.21 % | $ 70.2 M | ||
|
GeoVax Labs
GOVX
|
3.52 M | $ 1.54 | -1.6 % | $ 2.8 M | ||
|
Halozyme Therapeutics
HALO
|
177 M | $ 68.68 | -1.68 % | $ 8.23 B | ||
|
AgeX Therapeutics
AGE
|
5.91 M | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
58.7 M | - | - | $ 1.01 B | ||
|
Hoth Therapeutics
HOTH
|
831 K | $ 1.0 | -2.34 % | $ 6.38 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
25.2 M | - | - | $ 26.5 M | ||
|
Harmony Biosciences Holdings
HRMY
|
252 M | $ 28.29 | -2.11 % | $ 1.63 B | ||
|
AIkido Pharma
AIKI
|
3.78 M | - | 1.93 % | $ 17.4 M | ||
|
Agenus
AGEN
|
256 M | $ 3.2 | -4.19 % | $ 1.15 M | ||
|
Ayala Pharmaceuticals
AYLA
|
7.54 M | - | - | $ 7.46 M | ||
|
Akero Therapeutics
AKRO
|
39.8 M | - | - | $ 3.67 B | ||
|
Agios Pharmaceuticals
AGIO
|
82.2 M | $ 28.5 | -2.41 % | $ 1.65 B | ||
|
ImmuCell Corporation
ICCC
|
4.41 M | $ 6.24 | -4.66 % | $ 51 M | ||
|
IDEAYA Biosciences
IDYA
|
58.8 M | $ 35.14 | 6.34 % | $ 3.11 B | ||
|
Advaxis
ADXS
|
25 M | - | -9.65 % | $ 45.9 M | ||
|
Akouos
AKUS
|
16.8 M | - | 0.23 % | $ 488 M |